Xinda Bio refinanced HK$4.671 billion through the distribution

announced on the evening of January 22nd that all conditions for the allocation had been met and that the completion of the allocation had taken place on the same day. According to the announcement, a total of 52 million shares of Xinda Bio have been successfully issued by the distribution agent to not less than six contractors in accordance with the terms and conditions of the rights issue agreement, with a distribution price of HK$90.90 per share, resulting in a net proceeds of about HK$4.671 billion.Generally speaking, the main refinancing methods of listed companies in the Hong Kong stock market are divided into four types: share offering, distribution, public offering and cost issuance. A distribution is a targeted offering of shares by an H-share listed company to a specific institution. According to the LISTING Rules of hkex, listed companies generally require shareholders to give general authorization to the board of directors through the annual general meeting of shareholders, and after the company has obtained authorization, it may make any rights issue during the year as long as the proportion of the issue does not exceed 20% of the share capital on the day of approval by the shareholders' meeting and the offer price discount does not exceed 20%.According to the announcement on January 15th, the net proceeds from the Xinta Bio distribution will be used to: (1) accelerate the investment and development of the Company's global leading innovative products in a number of clinical trial programs; (Medical Rubik's Cube)